Globe-sparing surgical treatment for periocular malignancies with anterior orbital invasion: a consecutive case series

References

• Milman T, McCormick SA. The molecular genetics of eyelid tumors: recent advances and future directions. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):419–433. doi:10.1007/s00417-012-2248-5.
   PubMed Web of Science ®Google Scholar
• Kirzhner M, Karcioğlu ZA. Eyelid and periocular skin tumors. In: Karcioğlu Z ed. Orbital Tumors: Diagnosis and Treatment. New York: Springer; 2015:pp. 259–276. doi:10.1007/b138583.
   Google Scholar
• Shields CL, Alset AE, Boal NS, Casey MG, Knapp AN, Sugarman JA, et al. Conjunctival tumors in 5002 cases. comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen lecture. Am J Ophthalmol. 2017;173:106–133. doi:10.1016/j.ajo.2016.09.034.
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan lecture. Arch Ophthalmol. 1997;115(6):808–815. doi:10.1001/archopht.1997.01100150810025.
   PubMedGoogle Scholar
• Zhang Z, Ho S, Yin V, Varas G, Rajak S, Dolman PJ, et al. Multicentred international review of orbital exenteration and reconstruction in oculoplastic and orbit practice. Br J Ophthalmol. 2018;102(5):654–658. doi:10.1136/bjophthalmol-2017-310681.
   PubMed Web of Science ®Google Scholar
• Paridaens AD, McCartney AC, Lavelle RJ, Hungerford JL. Nasal and orbital recurrence of conjunctival melanoma 21 years after exenteration. Br J Ophthalmol. 1992;76(6):369–371. doi:10.1136/bjo.76.6.369.
   PubMed Web of Science ®Google Scholar
• Paridaens AD, McCartney AC, Minassian DC, Hungerford JL. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994;78(7):520–528. doi:10.1136/bjo.78.7.520.
   PubMed Web of Science ®Google Scholar
• Rahman I, Cook AE, Leatherbarrow B. Orbital exenteration: a 13 year Manchester experience. Br J Ophthalmol. 2005;89(10):1335–1340. doi:10.1136/bjo.2004.062471.
   PubMed Web of Science ®Google Scholar
• Madge SN, Khine AA, Thaller VT, Davis G, Malhotra R, McNab A, et al. Globe-sparing surgery for medial canthal basal cell carcinoma with anterior orbital invasion. Ophthalmology. 2010;117(11):2222–2228.doi:10.1016/j.ophtha.2010.02.013.
   PubMed Web of Science ®Google Scholar
• Patrinely JR, O’Neal KD, Kersten RC, Soparkar CN. Total upper eyelid reconstruction with mucosalized tarsal graft and overlying bipedicle flap. Arch Ophthalmol. 1999;117(12):1655–1661. doi:10.1001/archopht.117.12.1655.
   PubMedGoogle Scholar
• Paarlberg JC, van den Bosch WA, Paridaens D. Reconstruction following subtotal full-thickness upper eyelid resection with preservation of the lid margin. Orbit. 2007;26(4):319–321. doi:10.1080/01676830600972690.
   PubMedGoogle Scholar
• Sun MT, Wu A, Figueira E, Huilgol S, Selva D. Management of periorbital basal cell carcinoma with orbital invasion. Future Oncol. 2015;11(22):3003–3010. doi:10.2217/fon.15.190.
   PubMed Web of Science ®Google Scholar
• Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112(4):717–723. doi:10.1016/j.ophtha.2004.11.036.
   PubMed Web of Science ®Google Scholar
• Iuliano A, Strianese D, Uccello G, Diplomatico A, Tebaldi S, Bonavolontà G. Risk factors for orbital exenteration in periocular basal cell carcinoma. Am J Ophthalmol. 2012;153(2):238–241.e1. doi:10.1016/j.ajo.2011.08.004.
   PubMed Web of Science ®Google Scholar
• Allen RC. Surgical management of periocular cancers: high- and low-risk features drive treatment. Curr Oncol Rep. 2017;19(9):57. doi:10.1007/s11912-017-0618-1.
   PubMed Web of Science ®Google Scholar
• Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33(2):159–169. doi:10.1016/j.clindermatol.2014.10.008.
   PubMed Web of Science ®Google Scholar
• Connor M, Droll L, Ivan D, Cutlan J, Weber RS, Frank SJ, et al. Management of perineural invasion in sebaceous carcinoma of the eyelid. Ophthalmic Plast Reconstr Surg. 2011;27(5):356–359. doi:10.1097/IOP.0b013e3182163653.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Brodell RT, Bordeaux J, Honda K. The art and science of surgical margins for the dermatopathologist. Am J Dermatopathol. 2012;34(7):737–745. doi:10.1097/DAD.0b013e31823347cb.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Youssef A, Naderi A, Ahmadi AM, Meyer DR, McNab A, et al. Margins of excision for cutaneous melanoma of the eyelid skin: the collaborative eyelid skin melanoma group report. Ophthalmic Plast Reconstr Surg. 2003;19(2):96.doi:10.1097/01.IOP.0000056141.97930.E8.
   PubMed Web of Science ®Google Scholar
• Robert Bernardino C Managing periocular skin malignancies with mohs micrographic surgery. https://www.aao.org/current-insight/managing-periocular-skin-malignancies-with-mohs-mi. Published July 01, 2006. Accessed February 15, 2022.
   Google Scholar
• Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984;73(3):492–497. doi:10.1097/00006534-198403000-00030.
   PubMed Web of Science ®Google Scholar
• Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204. doi:10.1586/17469899.2014.921119.
   PubMedGoogle Scholar
• El-Hadad C, Rubin ML, Nagarajan P, Ford JR, Xu S, Ning J, et al. Prognostic factors for orbital exenteration, local recurrence, metastasis, and death from disease in conjunctival squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2021;37(3):262–268. doi:10.1097/IOP.0000000000001798.
   PubMed Web of Science ®Google Scholar
• Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, et al. Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol. 2019;20(12):e699–714. doi:10.1016/S1470-2045(19)30673-4.
   PubMed Web of Science ®Google Scholar
• Shepler TR, Prieto VG, Diba R, Neuhaus RW, Shore JW, Esmaeli B. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2006;22(2):113–115. doi:10.1097/01.iop.0000202609.92772.c3.
   PubMed Web of Science ®Google Scholar
• El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–1611. doi:10.1001/archophthalmol.2012.2515.
   PubMedGoogle Scholar
• Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703. doi:10.1056/NEJMoa1210093.
   PubMed Web of Science ®Google Scholar
• Hong BY, Ford JR, Glitza IC, Torres Cabala CA, Tetzlaff M, Prieto VG, et al. Immune checkpoint inhibitor therapy as an eye-preserving treatment for locally advanced conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2021;37(1):e9–13. doi:10.1097/IOP.0000000000001700.
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck [published correction appears in Clin Cancer Res. Clin Cancer Res. 2021 Apr 14;28(8):1735]. 2022;27(16):4557–4565. doi:10.1158/1078-0432.CCR-21-0585.
   Web of Science ®Google Scholar
• Karcioglu ZA, Wagoner MD. Demographics, etiology, and behavior of conjunctival squamous cell carcinoma in the 21st century. Ophthalmology. 2009;116(11):2045–2046. doi:10.1016/j.ophtha.2009.09.031.
   PubMed Web of Science ®Google Scholar